Key events, in time order
Shares fall despite beat, indicating mixed market reaction
Q2 VYJUVEK global revenue up 24% YoY, but pre-market shares fell 9.1% on sequential growth concerns.
Multiple independent sources confirm earnings timing, a key market event
Two independent sources同日发布看多报告，强调Vyjuvek国际上市及盈利自足
Fifth Third Bancorp raised stake by 3,958.2% in Q1; company to report Q2 results on Aug 3
None yet
None yet
A director at Krystal Biotech sold a significant number of shares, marking their largest sale to date. This event is being discussed as a potential indicator of insider sentiment.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Krystal Biotech makes redosable gene therapies for rare skin diseases, like a genetic repair kit applied directly to the skin, with its lead treatment for a severe blistering condition in late-stage trials.
Revenue comes from selling its approved gene therapy, with gross margins around 93% and net margins near 55%, showing highly profitable, recurring treatment sales.
Its proprietary redosable gene therapy platform is hard to replicate, but competitors like Abeona Therapeutics and Castle Creek Biosciences are advancing rival treatments for the same disease, eroding its first-mover edge.
